About Aeterna Zentaris
Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in the development and commercialization of therapeutics and diagnostic tests.
Aeterna Zentaris’ Markets Macimorelin: The company markets macimorelin under the brand name Macrilen. Macimorelin is an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates growth hormone secretion by binding to the GHSR-1a for the diagnosis of growth hormone deficiency in adults and in children, as well as for oncology indications. Macrilen™ is currently marketed in the United States under a licensing agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside the United States and Canada.
The Company Has Licensing Agreement With Research Institutes:
Aeterna Zentaris Inc. has a license agreement with the College of Wuerzburg, Germany, to research, develop, manufacture and commercialize a potential COVID -19 vaccine; to develop, manufacture and commercialize a treatment for neuromyelitis optica spectrum disorder; to develop 3D human intestinal tissue models to study infection biology; and for preclinical development for the potential treatment of Parkinson's disease. In addition, the Company has a license agreement with Consilient Health Ltd, Novo Nordisk Novo Nordisk Health Care AG and NK MEDITECH Ltd for the development and commercialization of macimorelin in the United States and Canada, and with the College of Sheffield, United Kingdom, for the research, development, manufacture and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism.
Aeterna’s Mission Is Focused on Leveraging its Research and Clinical Development: The company is focused on leveraging its research and clinical development expertise to develop medicines that improve the lives of patients with high unmet medical needs across a range of therapeutic areas.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Aeterna Zentaris
New York City, US
28 Aug 2023
Æterna Zentaris (Biotech company)
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD).cnbc.com/quotes/AEZS#:~:text=MORE-,Aeterna%20Zentaris%20Inc.,growth%20hormone%20deficiency%20(AGHD).
Stock price : AEZS (NASDAQ) $2.74 -0.03 (-1.08%)Aug 25, 4:00 PM EDT - Disclaimer
Headquarters : Charleston, SC
Subsidiary : Æterna Zentaris GmbH
Founded : 1990